《中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤诊断与治疗指南（2025年版）》
[The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2025)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):105-112. doi: 10.3760/cma.j.cn121090-20241209-00551.
Abstract
Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL) is a mature B cell neoplasm with specific immunophenotype, mainly occurs in the middle-aged and elderly population. In recent years, there has been significant progress in the basic and clinical research of CLL/SLL, especially in the field of new drug treatments. To improve the diagnostic, differential diagnostic, and standardized treatment levels of CLL/SLL for medical workers in China, Hematological Oncology Committee of China Anti-Cancer Association, Hematology Committee of Chinese Medical Association, Chinese Working Group for Chronic Lymphocytic Leukemia have revised the guidelines for the diagnosis and treatment of Chinese CLL/SLL (2022 edition) and formulated this version of the guidelines.
摘要
慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）是一种具有特定免疫表型的成熟B细胞肿瘤，主要发生于中老年人群。近年来，CLL/SLL的基础与临床研究取得了显著进展，尤其是在新药治疗领域。为提高我国医务工作者对CLL/SLL的诊断、鉴别诊断及规范化治疗水平，中国抗癌协会血液肿瘤专业委员会、中华医学会血液学分会、中国慢性淋巴细胞白血病工作组对《中国CLL/SLL诊断与治疗指南（2022年版）》进行修订，制定了本版指南。
相似文献
1
[The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2025)].《中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤诊断与治疗指南（2025年版）》
Zhonghua Xue Ye Xue Za Zhi. 2025 Feb 14;46(2):105-112. doi: 10.3760/cma.j.cn121090-20241209-00551.
2
Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.小淋巴细胞淋巴瘤在慢性淋巴细胞白血病临床试验中的代表性不足。
Eur J Haematol. 2025 Apr;114(4):636-640. doi: 10.1111/ejh.14376. Epub 2024 Dec 27.
3
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.NCCN 指南解读：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，第 1.2017 版。
J Natl Compr Canc Netw. 2017 Mar;15(3):293-311. doi: 10.6004/jnccn.2017.0030.
4
Monoclonal B-cell lymphocytosis in the bone marrow: revisiting the criteria for chronic lymphocytic leukemia/small lymphocytic lymphoma.骨髓中单克隆 B 细胞淋巴增生：重新审视慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的标准。
Hum Pathol. 2022 Jul;125:108-116. doi: 10.1016/j.humpath.2022.04.010. Epub 2022 Apr 25.
5
The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia/small lymphocytic lymphoma from a large single Chinese center.来自中国一个大型单一中心的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中白血病细胞浸润肾间质的病理特征。
Diagn Pathol. 2021 Jul 4;16(1):59. doi: 10.1186/s13000-021-01120-4.
6
Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).B 细胞慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（B-CLL/SLL）和套细胞淋巴瘤（MCL）的诊断与预后
J Egypt Natl Canc Inst. 2005 Dec;17(4):279-90.
7
Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤与其他惰性淋巴瘤（包括套细胞淋巴瘤）的鉴别诊断。
J Clin Exp Hematop. 2020 Dec 15;60(4):124-129. doi: 10.3960/jslrt.19041. Epub 2020 Apr 3.
8
[Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research].中国慢性淋巴细胞白血病的诊断与治疗现状：一项全国多中心调查研究
Zhonghua Xue Ye Xue Za Zhi. 2023 May 14;44(5):380-387. doi: 10.3760/cma.j.issn.0253-2727.2023.05.005.
9
Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.慢性淋巴细胞白血病和小淋巴细胞淋巴瘤：同一疾病的两种表现。
Expert Rev Hematol. 2017 Feb;10(2):137-146. doi: 10.1080/17474086.2017.1270203. Epub 2016 Dec 26.
10
Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).血液学家/肿瘤学家的疾病专业知识与生存：慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）的经验教训。
Cancer. 2012 Apr 1;118(7):1827-37. doi: 10.1002/cncr.26474. Epub 2011 Aug 26.
本文引用的文献
1
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience.维奈克拉联合剂量调整的 R-EPOCH（VR-DA-EPOCH）或 G-EPOCH 桥接后续细胞治疗转化淋巴瘤患者的单中心临床经验。
Ann Hematol. 2024 May;103(5):1635-1642. doi: 10.1007/s00277-024-05618-x. Epub 2024 Jan 22.
2
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.伊布替尼联合氟达拉滨、环磷酰胺和利妥昔单抗（iFCR）作为伴有或不伴有TP53异常的慢性淋巴细胞白血病/小淋巴细胞白血病的初始治疗：一项中国队列的前瞻性真实世界研究
Blood Cancer J. 2023 Aug 9;13(1):121. doi: 10.1038/s41408-023-00890-y.
3
[Expert Consensus on the prevention and treatment of indolent B-cell non-Hodgkin lymphoma with novel coronavirus infection].[新型冠状病毒感染惰性B细胞非霍奇金淋巴瘤防治专家共识]
Zhonghua Yi Xue Za Zhi. 2023 Jul 11;103(26):1980-1985.
4
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia.中国慢性淋巴细胞白血病患者中MYD88和KMT2D突变的高发生率。
Leukemia. 2021 Aug;35(8):2412-2415. doi: 10.1038/s41375-021-01124-5. Epub 2021 Jan 22.
5
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.泽布替尼治疗复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的疗效：一项 2 期、单臂、多中心研究。
J Hematol Oncol. 2020 May 11;13(1):48. doi: 10.1186/s13045-020-00884-4.
6
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.伊布替尼联合利妥昔单抗与化疗免疫治疗慢性淋巴细胞白血病的比较
N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.
7
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.维奈托克联合奥滨尤妥珠单抗治疗伴有合并症的 CLL 患者
N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.
8
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.伊布替尼方案与化疗免疫治疗在未经治疗的老年 CLL 患者中的比较。
N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.
9
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病。
N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.
10
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.iwCLL 指南：用于 CLL 的诊断、治疗指征、疗效评估和支持性管理。
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
Zotero 插件